INCYTE CORP annual report, FY2021

Full document

Incyte Corporation (NASDAQ: INCY) — FY2021 Form 10-K

Reporting period: Fiscal year ended December 31, 2021; comparisons are to FY2020 unless noted. Incyte is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics, with commercial products in hematology/oncology and dermatology and royalty-generating licensing collaborations.

Financial performance and liquidity

  • Revenue: $2.986 billion, up 12.0% from $2.667 billion. Product revenue was $2.322 billion (+12.2%); royalties were $569.3 million (+44.9%); milestone and contract revenue was $95.0 million, down from $205.0 million.
  • Product concentration: JAKAFI revenue was $2.135 billion, up from $1.938 billion, and remained the company’s largest revenue source. JAKAVI royalties were $338.0 million; OLUMIANT royalties were $220.9 million.
  • Profitability: Operating income was $585.8 million versus an operating loss of $263.7 million. Net income was $948.6 million, or $4.27 diluted EPS, versus a net loss of $295.7 million, or $1.36 per diluted share. The 2021 result included a $569.0 million deferred-tax valuation-allowance release; reported income-tax benefit was $378.1 million. Thus, net income was materially affected by a non-cash tax item.
  • Expenses: R&D was $1.458 billion, down from $2.216 billion, primarily reflecting lower collaboration-related and other outside costs versus 2020. SG&A rose to $739.6 million from $516.9 million, including increased commercialization and OPZELURA launch costs and a legal settlement. Cost of product revenue was $151.0 million.
  • Cash flow: Operating activities provided $749.5 million, compared with $124.6 million used in 2020. Investing activities used $207.7 million, including $181.0 million in capital expenditures; financing activities provided $6.2 million.
  • Liquidity and obligations: Cash, cash equivalents and marketable securities totaled $2.348 billion, versus $1.801 billion; working capital was $2.264 billion. Incyte had no borrowings under its $500 million three-year revolving credit facility at year-end. The balance sheet included $244.0 million of acquisition-related contingent consideration and $34.3 million of finance-lease liabilities; these are not reported as funded borrowings.
  • Margins: Operating margin was approximately 19.6% (2020: approximately negative 9.9%). Net margin was approximately 31.8%, but is elevated by the tax benefit. The filing does not present a single consolidated gross-margin measure that is directly comparable across its product and royalty revenue streams.

Material changes and business developments

  • FDA approved JAKAFI for chronic GVHD in September 2021, expanding its approved indications.
  • OPZELURA cream was approved for atopic dermatitis in September 2021 and launched in October; Incyte established a dermatology commercial franchise. Initial 2021 sales were $4.7 million.
  • PEMAZYRE received approvals in Japan and the European Union; 2021 revenue was $68.5 million versus $25.9 million.
  • MINJUVI received conditional European Commission authorization; 2021 revenue was $4.9 million. MONJUVI/MINJUVI is partnered with MorphoSys.
  • Royalty growth reflected higher partner sales, particularly for OLUMIANT and JAKAVI. Milestone revenue declined because 2020 included $170 million under the Novartis agreement, compared with $95 million total milestone and contract revenue in 2021.
  • Incyte entered an axatilimab collaboration with Syndax, paying a $117 million upfront fee; it also recognized a $10.2 million R&D expense for the premium on its Syndax share purchase.
  • Employees increased 18% to 2,094, largely in preparation for the OPZELURA launch. Property and equipment rose to $723.9 million, with substantial construction spending.

Outlook, risks and unusual items

  • The filing provides no specific FY2022 revenue, earnings or cash-flow guidance. Management said existing cash, operating cash flow and the undrawn revolving facility should meet capital needs for the foreseeable future, while noting spending depends on R&D, commercialization, facilities and strategic transactions.
  • Management identified reliance on JAKAFI as a significant business risk; JAKAFI remains a large share of revenue. Other key exposures include reimbursement and pricing pressure, competition, product safety and regulatory changes, patent challenges and reliance on third-party manufacturers and a limited number of distribution customers.
  • FDA labeling updates added JAK-inhibitor class warnings concerning cardiovascular events, thrombosis and secondary malignancies. The filing says the potential effect on JAKAFI and OPZELURA demand is uncertain.
  • COVID-19 had not materially affected commercial results or manufacturing supply to date, according to management, but had affected new patient starts and could disrupt clinical trials, laboratory work, regulatory timelines and supply chains.
  • In January 2022, after discussions with FDA, Incyte withdrew the parsaclisib U.S. application because confirmatory trials could not be completed within a reasonable period. Retifanlimab received an FDA complete response letter for anal cancer; Incyte withdrew its European application. Lilly discontinued baricitinib’s Phase III SLE program after mixed efficacy results.
  • In May 2021, Incyte agreed to pay $12.6 million plus statutory fees to settle a DOJ matter concerning speaker and patient-assistance programs; the company denied improper claims. The settlement was recorded in FY2021 SG&A.
  • JAKAFI’s composition-of-matter patent estate was expected to expire in 2027, with certain phosphate-salt patents extending to mid-2028, subject to applicable protections. A generic challenger had submitted an ANDA; the company states the FDA had taken no action on it to its knowledge.
  • The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. The company reported effective disclosure controls and financial reporting controls.

Most important facts for investors to verify

  • Underlying earnings and future tax expense excluding the $569.0 million valuation-allowance release; management expects future reported tax expense to be higher than in prior periods.
  • JAKAFI sales trends, indication mix, pricing and reimbursement, and developments in the pending generic challenge.
  • OPZELURA uptake, payer coverage and the commercial costs required to establish the dermatology franchise.
  • Progress and regulatory outcomes for major pipeline programs, including axatilimab, ruxolitinib combinations, tafasitamab and pemigatinib, and consequences of the parsaclisib withdrawal and retifanlimab CRL.
  • Cash generation relative to R&D, commercial spending, the $117 million axatilimab upfront payment and ongoing facility investment; also monitor the completion and approval of the Swiss biologics facility, expected in the second half of 2022.
  • Changes in rebates and chargebacks, which affect reported net product revenue, and fair-value movements in collaboration-partner investments and ICLUSIG-related contingent consideration.